Anti-BD3 / Beta Defensin 3 Antibody (Biotin) (ARG56782)

Total Page：16

File Type：pdf, Size：1020Kb

Anti-BD3 / Beta Defensin 3 Antibody (Biotin) (ARG56782)

Product datasheet [email protected] ARG56782 Package: 50 μg anti-BD3 / beta Defensin 3 antibody (Biotin) Store at: 4°C Summary Product Description Biotin-conjugated Rabbit Polyclonal antibody recognizes BD3 / beta Defensin 3 Tested Reactivity Hu Tested Application ELISA, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name BD3 / beta Defensin 3 Antigen Species Human Immunogen E.coli derived Recombinant Human BD-3. (GIINTLQKYY CRVRGGRCAV LSCLPKEEQI GKCSTRGRKC CRRKK) Conjugation Biotin Alternate Names DEFB-3; HBD3; Beta-defensin 103; Defensin, beta 103; HBP3; Defensin-like protein; hBD-3; HBP-3; Beta- defensin 3; BD-3; DEFB3; DEFB103 Application Instructions Application table Application Dilution ELISA Direct: 0.25 - 1.0 µg/ml Sandwich: 0.25 - 1.0 µg/ml with ARG56672 as a capture antibody WB 0.1 - 0.2 µg/ml Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 8 kDa Properties Form Liquid Purification Purified by affinity chromatography. Buffer PBS (pH 7.2) Concentration 1 mg/ml Storage instruction Aliquot and store in the dark at 2-8°C. Keep protected from prolonged exposure to light. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. www.arigobio.com 1/2 Bioinformation Gene Symbol DEFB103A Gene Full Name defensin, beta 103A Background Defensins form a family of microbicidal and cytotoxic peptides made by neutrophils. Members of the defensin family are highly similar in protein sequence. This gene encodes defensin, beta 103, an antibiotic peptide which is induced by bacteria and interferon gamma, and which displays antimicrobial activity against S. aureus, S. pyogenes, P. aeruginosa, E. coli, and C. albicans. [provided by RefSeq, Oct 2014] Function Exhibits antimicrobial activity against Gram-positive bacteria S.aureus and S.pyogenes, Gram-negative bacteria P.aeruginosa and E.coli and the yeast C.albicans. Kills multiresistant S.aureus and vancomycin- resistant E.faecium. No significant hemolytic activity was observed. [UniProt] www.arigobio.com 2/2 Powered by TCPDF (www.tcpdf.org).

Copy Link

Recommended publications

Genome Sequence, Population History, and Pelage Genetics of the Endangered African Wild Dog (Lycaon Pictus) Michael G
Campana et al. BMC Genomics (2016) 17:1013 DOI 10.1186/s12864-016-3368-9 RESEARCH ARTICLE Open Access Genome sequence, population history, and pelage genetics of the endangered African wild dog (Lycaon pictus) Michael G. Campana1,2*, Lillian D. Parker1,2,3, Melissa T. R. Hawkins1,2,3, Hillary S. Young4, Kristofer M. Helgen2,3, Micaela Szykman Gunther5, Rosie Woodroffe6, Jesús E. Maldonado1,2 and Robert C. Fleischer1 Abstract Background: The African wild dog (Lycaon pictus) is an endangered African canid threatened by severe habitat fragmentation, human-wildlife conflict, and infectious disease. A highly specialized carnivore, it is distinguished by its social structure, dental morphology, absence of dewclaws, and colorful pelage. Results: We sequenced the genomes of two individuals from populations representing two distinct ecological histories (Laikipia County, Kenya and KwaZulu-Natal Province, South Africa). We reconstructed population demographic histories for the two individuals and scanned the genomes for evidence of selection. Conclusions: We show that the African wild dog has undergone at least two effective population size reductions in the last 1,000,000 years. We found evidence of Lycaon individual-specific regions of low diversity, suggestive of inbreeding or population-specific selection. Further research is needed to clarify whether these population reductions and low diversity regions are characteristic of the species as a whole. We documented positive selection on the Lycaon mitochondrial genome. Finally, we identified several candidate genes (ASIP, MITF, MLPH, PMEL) that may play a role in the characteristic Lycaon pelage. Keywords: Lycaon pictus, Genome, Population history, Selection, Pelage Background Primarily a hunter of antelopes, the African wild dog is a The African wild dog (Lycaon pictus) is an endangered highly distinct canine.
[Show full text]
32-12012: Human Beta Defensin-3 Description Product
9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982 Email: [email protected] 32-12012: Human Beta Defensin-3 Gene : DEFB103A Gene ID : 414325 Uniprot ID : P81534 Alternative Name : DEFB-3, Beta-defensin 3, Defensin, beta 103, Defensin-like protein Description Source: Genetically modified E.coli. Predicted MW: Monomer, 5.2 kDa (45 aa) Beta-Defensin 3 (BD-3), also known as DEFB-3, is a member of the defensin class of antimicrobial peptides. Beta defensins exert host defense responses against viruses, bacteria, and fungi through the binding and permeabilizing of microbial membranes. BD-3 expression is stimulated by interferon-gamma and is an important molecule during adaptive immunity. BD-3 functions to activate monocytes and mast cells, and has antibacterial functions towards Gram-negative and Gram-positive bacteria. Further, BD-3 blocks human immunodeficiency virus type 1 (HIV-1) replication through the downregulation of the HIV-1 co-receptor, CXCR4. Product Info Amount : 20 µg / 100 µg Purification : Reducing and Non-Reducing SDS PAGE at >= 95% Lyophilized from a sterile (0.2 micron) filtered aqueous solution containing 0.1% Trifluoroacetic Content : Acid (TFA) Sterile water at 0.1 mg/mL Storage condition : Store at -20°C Amino Acid : GIINTLQKYY CRVRGGRCAV LSCLPKEEQI GKCSTRGRKC CRRKK Application Note Endotoxin: Less than 0.1 ng/Âµg (1 IEU/Âµg) as determined by LAL test. Centrifuge vial before opening, Suspend the product by gently pipetting the above recommended solution down the sides of the vial. DO NOT VORTEX. Allow several minutes for complete reconstitution. For prolonged storage, dilute to working aliquots in a 0.1% BSA solution, store at -80Â°C and avoid repeat freeze thaws.
[Show full text]
Mapping DNA Structural Variation in Dogs
Downloaded from genome.cshlp.org on October 3, 2021 - Published by Cold Spring Harbor Laboratory Press Resource Mapping DNA structural variation in dogs Wei-Kang Chen,1,4 Joshua D. Swartz,1,4,5 Laura J. Rush,2 and Carlos E. Alvarez1,3,6 1Center for Molecular and Human Genetics, The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio 43205, USA; 2Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio 43210, USA; 3Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio 43210, USA DNA structural variation (SV) comprises a major portion of genetic diversity, but its biological impact is unclear. We propose that the genetic history and extraordinary phenotypic variation of dogs make them an ideal mammal in which to study the effects of SV on biology and disease. The hundreds of existing dog breeds were created by selection of extreme morphological and behavioral traits. And along with those traits, each breed carries increased risk for different diseases. We used array CGH to create the first map of DNA copy number variation (CNV) or SV in dogs. The extent of this variation, and some of the gene classes affected, are similar to those of mice and humans. Most canine CNVs affect genes, including disease and candidate disease genes, and are thus likely to be functional. We identified many CNVs that may be breed or breed class specific. Cluster analysis of CNV regions showed that dog breeds tend to group according to breed classes. Our combined findings suggest many CNVs are (1) in linkage disequilibrium with flanking sequence, and (2) associated with breed-specific traits.
[Show full text]
Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications
Stem Cell Rev and Rep DOI 10.1007/s12015-016-9662-8 Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications Behnam Ahmadian Baghbaderani 1 & Adhikarla Syama2 & Renuka Sivapatham3 & Ying Pei4 & Odity Mukherjee2 & Thomas Fellner1 & Xianmin Zeng3,4 & Mahendra S. Rao5,6 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract We have recently described manufacturing of hu- help determine which set of tests will be most useful in mon- man induced pluripotent stem cells (iPSC) master cell banks itoring the cells and establishing criteria for discarding a line. (MCB) generated by a clinically compliant process using cord blood as a starting material (Baghbaderani et al. in Stem Cell Keywords Induced pluripotent stem cells . Embryonic stem Reports, 5(4), 647–659, 2015). In this manuscript, we de- cells . Manufacturing . cGMP . Consent . Markers scribe the detailed characterization of the two iPSC clones generated using this process, including whole genome se- quencing (WGS), microarray, and comparative genomic hy- Introduction bridization (aCGH) single nucleotide polymorphism (SNP) analysis. We compare their profiles with a proposed calibra- Induced pluripotent stem cells (iPSCs) are akin to embryonic tion material and with a reporter subclone and lines made by a stem cells (ESC) [2] in their developmental potential, but dif- similar process from different donors. We believe that iPSCs fer from ESC in the starting cell used and the requirement of a are likely to be used to make multiple clinical products. We set of proteins to induce pluripotency [3]. Although function- further believe that the lines used as input material will be used ally identical, iPSCs may differ from ESC in subtle ways, at different sites and, given their immortal status, will be used including in their epigenetic profile, exposure to the environ- for many years or even decades.
[Show full text]
Elucidation of Dose-Dependent Transcriptional Events Immediately Following Ionizing Radiation Exposure
bioRxiv preprint doi: https://doi.org/10.1101/207951; this version posted October 23, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 2 3 4 Elucidation of dose-dependent transcriptional events immediately following 5 ionizing radiation exposure 6 7 Eric C. Rouchka1,2,*, Robert M. Flight3, Brigitte H. Fasciotto4, Rosendo Estrada5, John W. 8 Eaton6,7,8, Phani K. Patibandla5, Sabine J. Waigel8, Dazhuo Li1, John K. Kirtley1, Palaniappan 9 Sethu9,10, and Robert S. Keynton5 10 11 1Department of Computer Engineering and Computer Science, University of Louisville, 12 Louisville, Kentucky, United States of America 13 14 2Kentucky Biomedical Research Infrastructure Network Bioinformatics Core, University of 15 Louisville, Louisville, Kentucky, United States of America 16 17 3Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, 18 Kentucky, United States of America 19 20 4The ElectroOptics Research Institute and Nanotechnology Center, University of Louisville, 21 Louisville, Kentucky, United States of America 22 23 5Department of Bioengineering, University of Louisville, Louisville, Kentucky, United States of 24 America 25 26 6Department of Medicine, University of Louisville, Louisville, Kentucky, United States of 27 America 28 29 7Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, 30 United States of America 31 32 8James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, United 33 States of America 34 35 9Division of Cardiovascular Disease, Department of Medicine, University of Alabama at 36 Birmingham, Birmingham, Alabama, United States of America 37 38 10Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, 39 Alabama, United States of America 1 bioRxiv preprint doi: https://doi.org/10.1101/207951; this version posted October 23, 2017.
[Show full text]
High-Resolution Analysis of Chromosomal Alterations in Adult Acute Lymphoblastic Leukemia
Elmer Press Original Article J Hematol. 2014;3(3):65-71 High-Resolution Analysis of Chromosomal Alterations in Adult Acute Lymphoblastic Leukemia Lam Kah Yuena, c, Zakaria Zubaidaha, Ivyna Bong Pau Nia, Megat Baharuddin Puteri Jamilatul Noora, Esa Ezaliaa, Chin Yuet Menga, Ong Tee Chuanb, Vegappan Subramanianb, Chang Kiang Mengb Abstract Introduction Background: Chromosomal alterations occur frequently in acute Acute lymphoblastic leukemia (ALL) is a heterogeneous lymphoblastic leukemia (ALL), affecting either the chromosome disease, resulting from the accumulation of chromosomal al- number or structural changes. These alterations can lead to inacti- terations either in the form of numerical or structural chang- vation of tumor suppressor genes and/or activation of oncogenes. es such as amplification, deletion, inversion or translocation. The objective of this study was to identify recurrent and/or novel The frequency of chromosomal alterations in adult ALL is chromosomal alterations in adult ALL using single nucleotide poly- 64-85% [1], compared to 60-69% in childhood ALL. Trans- morphism (SNP) array analysis. location t(9.22), one of the most common recurring chromo- Methods: We studied 41 cases of adult ALL compared with healthy somal alterations, is found in 20-40% adult ALL patients [2], normal controls using SNP array. and its incidence increases with age. Some of the chromo- somal alterations are significantly associated with remission Results: Our analysis revealed 43 copy number variant regions, duration, complete remission rate and disease-free survival of which 44% were amplifications and 56% were deletions. The [1]. Increasing age is also associated with lower remission most common amplifications were on chromosome regions 8p23.1 rates, shorter remissions and poor outcomes in adult ALL (71%), 1q44 (66%), 1q23.3 (54%), 11q23.3 (54%), 12p13.33 [1].
[Show full text]
Measurement of Copy Number at Complex Loci Using High-Throughput Sequencing Data
METHODS ARTICLE published: 01 August 2014 doi: 10.3389/fgene.2014.00248 The CNVrd2 package: measurement of copy number at complex loci using high-throughput sequencing data HoangT.Nguyen1,2,3,TonyR.Merriman1,3* and Michael A. Black 1,3 1 Department of Biochemistry, University of Otago, Dunedin, New Zealand 2 Department of Mathematics and Statistics, University of Otago, Dunedin, New Zealand 3 Department of Biochemistry, Virtual Institute of Statistical Genetics, University of Otago, Dunedin, New Zealand Edited by: Recent advances in high-throughout sequencing technologies have made it possible to Alexandre V. Morozov, Rutgers accurately assign copy number (CN) at CN variable loci. However, current analytic methods University, USA often perform poorly in regions in which complex CN variation is observed. Here we Reviewed by: report the development of a read depth-based approach, CNVrd2, for investigation of David John Studholme, University of Exeter, UK CN variation using high-throughput sequencing data. This methodology was developed Mikhail P.Ponomarenko, Institute of using data from the 1000 Genomes Project from the CCL3L1 locus, and tested using Cytology and Genetics of Siberian data from the DEFB103A locus. In both cases, samples were selected for which paralog Branch of Russian Academy of ratio test data were also available for comparison. The CNVrd2 method ﬁrst uses Sciences, Russia observed read-count ratios to reﬁne segmentation results in one population. Then a *Correspondence: Tony R. Merriman, Department of linear regression model is applied to adjust the results across multiple populations, in Biochemistry, University of Otago, combination with a Bayesian normal mixture model to cluster segmentation scores into 710 Cumberland Street, Dunedin groups for individual CN counts.
[Show full text]
DUX4 Activates Germline Genes, Retroelements, and Immune Mediators: Implications for Facioscapulohumeral Dystrophy
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Developmental Cell Article DUX4 Activates Germline Genes, Retroelements, and Immune Mediators: Implications for Facioscapulohumeral Dystrophy Linda N. Geng,1,7 Zizhen Yao,2,7 Lauren Snider,1 Abraham P. Fong,1 Jennifer N. Cech,1 Janet M. Young,1 Silvere M. van der Maarel,3 Walter L. Ruzzo,4 Robert C. Gentleman,5 Rabi Tawil,6 and Stephen J. Tapscott1,* 1Division of Human Biology 2Division of Public Health Sciences Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA 3Department of Human Genetics, Leiden University Medical Center, 2333ZA Leiden, The Netherlands 4Departments of Computer Science and Engineering and Genome Sciences, University of Washington, Seattle, WA 98105, USA 5Bioinformatics and Computational Biology, Genentech, South San Francisco, CA 94080, USA 6Department of Neurology, University of Rochester, Rochester, NY 14627, USA 7These authors contributed equally to this work *Correspondence: [email protected] DOI 10.1016/j.devcel.2011.11.013 SUMMARY 1996). Each repeat unit contains a copy of the double homeobox retrogene DUX4 (Clapp et al., 2007; Gabrie¨ ls et al., 1999; Lyle Facioscapulohumeral dystrophy (FSHD) is one of et al., 1995), and inappropriate expression of DUX4 was initially the most common inherited muscular dystrophies. proposed as a possible cause of FSHD. This was supported The causative gene remains controversial and the by the observations that repeat contraction is associated with mechanism of pathophysiology unknown. Here we decreased repressive epigenetic marks in the remaining D4Z4 identify genes associated with germline and early units (van Overveld et al., 2003; Zeng et al., 2009) and that over- stem cell development as targets of the DUX4 tran- expression of the DUX4 protein in a variety of cells, including skeletal muscle, causes apoptotic cell death (Kowaljow et al., scription factor, a leading candidate gene for FSHD.
[Show full text]
Distribution of Human H-Defensin Polymorphisms in Various Control and Cystic Fibrosis Populations
Genomics 85 (2005) 574 – 581 www.elsevier.com/locate/ygeno Distribution of human h-defensin polymorphisms in various control and cystic fibrosis populations Anne Vankeerberghena,1, Olga Scudierob,1, Kris De Boeckc, Milan Macek Jr.d, Pier Franco Pignattie, Noe´mi Van Hula, Hilde Nuyttena, Francesco Salvatoreb, Giuseppe Castaldob, Daniela Zemkovad, Vera Vavrovad, Jean-Jacques Cassimana, Harry Cuppensa,T aDepartment of Human Genetics, KULeuven, Herestraat 49, O&N6, 3000 Louvain, Belgium bDepartment of Biochemistry and Medical Biotechnology–CEINGE, University of Naples Federico II, Naples, Italy cDepartment of Pediatrics, UZ Gasthuisberg, Herestraat 49, 3000 Louvain, Belgium dInstitute of Biology and Medical Genetics and Department of Pediatrics, Charles University Prague and University Hospital Motol, Cystic Fibrosis Center, V Uvalu 84, CZ 15006 Prague, Czech Republic eSection of Biology and Genetics, Department of Mother and Child, Biology and Genetics, University of Verona, Verona, Italy Received 12 December 2004; accepted 7 February 2005 Abstract Human h defensins contribute to the first line of defense against infection of the lung. Polymorphisms in these genes are therefore potential modifiers of the severity of lung disease in cystic fibrosis. Polymorphisms were sought in the human h-defensin genes DEFB1, DEFB4, DEFB103A, and DEFB104 in healthy individuals and cystic fibrosis (CF) patients living in various European countries. DEFB1, DEFB4, and DEFB104 were very polymorphic, but DEFB103A was not. Within Europe, differences between control populations were found for some of the frequent polymorphisms in DEFB1, with significant differences between South-Italian and Czech populations. Moreover, frequent polymorphisms located in DEFB4 and DEFB104 were not in Hardy Weinberg equilibrium in all populations studied, while those in DEFB1 were in Hardy Weinberg equilibrium.
[Show full text]
Teleost Fish-Specific Preferential Retention of Pigmentation Gene
INVESTIGATION Teleost Fish-Specific Preferential Retention of Pigmentation Gene-Containing Families After Whole Genome Duplications in Vertebrates Thibault Lorin,*,1 Frédéric G. Brunet,* Vincent Laudet,† and Jean-Nicolas Volff* *Institut de Génomique Fonctionnelle de Lyon, École Normale Supérieure de Lyon, UMR 5242 CNRS, Université Claude Bernard Lyon I, Université de Lyon, 46 Allée d’Italie, 69364 Lyon Cedex 07, France and †Observatoire Océanologique de Banyuls-sur-Mer, UMR CNRS 7232 BIOM; Sorbonne Université; 1, Avenue Pierre Fabre, 66650 Banyuls-sur-Mer, France ORCID IDs: 0000-0001-5145-8925 (F.G.B.); 0000-0003-4022-4175 (V.L.); 0000-0003-3406-892X (J.-N.V.) ABSTRACT Vertebrate pigmentation is a highly diverse trait mainly determined by neural crest cell KEYWORDS derivatives. It has been suggested that two rounds (1R/2R) of whole-genome duplications (WGDs) at the pigmentation basis of vertebrates allowed changes in gene regulation associated with neural crest evolution. Sub- chromatophores sequently, the teleost fish lineage experienced other WGDs, including the teleost-specific Ts3R before vertebrates teleost radiation and the more recent Ss4R at the basis of salmonids. As the teleost lineage harbors the teleost highest number of pigment cell types and pigmentation diversity in vertebrates, WGDs might have whole-genome contributed to the evolution and diversification of the pigmentation gene repertoire in teleosts. We have duplication compared the impact of the basal vertebrate 1R/2R duplications with that of the teleost-specific Ts3R and salmonid-specific Ss4R WGDs on 181 gene families containing genes involved in pigmentation. We show that pigmentation genes (PGs) have been globally more frequently retained as duplicates than other genes after Ts3R and Ss4R but not after the early 1R/2R.
[Show full text]
Product Information/Manual
EKA51820 - 96 Tests BD-3 Colorimetric Sandwich ELISA Kit Species Reactivity: Human FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES Last Updated: March 2021 INSTRUCTION MANUAL This manual may be updated as a result of continuous improvements. Please always refer to the hard copy manual included in the kit for your experiment. Biomatik has been trusted by 10,000+ scientists since 2002. View thousands of publications citing Biomatik’s fine products at Google Scholar Biomatik Corporation 519-489-7195 | [email protected] | www.biomatik.com CONTENTS PAGE Introduction………………………………………………..…………….………..3 Assay Principles……………………………………………………….…………4 Assay Format………………………………………………………………..……5 Assay Restrictions……………………………………………………….……….6 Materials Included……………………………………………….……………….6 Additional Materials Required…………………………………………….…….7 Health and Safety Precautions…………………………………………….…...7 Storage Information………………………………………………………….…..8 Sample Preparation and Storage……………………………………………….9 Sample Experiment Layout…………………………………………………....10 Immunoassay Protocol……………………………………….…………….…..11 Summarized Protocol………………………………………………………......16 Sensitivity………………………………………………………………………..17 Cross Reactivity and Specificity……………………………………….…...…17 Technical Support……………………………………………….……………...18 ELISA Plate Template……………………………………………………..…...19 Notes…………………………………………………………….……………….20 Biomatik Corporation 519-489-7195 | [email protected] | www.biomatik.com 2 INTRODUCTION Human BD-3, also known as Beta-Defensin 3, is a 67 amino acid cytokine protein encoded by the
[Show full text]
In a Single Wei Inset Patent Application Publication Aug
US 20150217131A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0217131 A1 Titova et al. (43) Pub. Date: Aug. 6, 2015 (54) TERAHERTZ PULSE RADATION IN Publication Classification TREATING SKINDSORDERS (51) Int. Cl. (71) Applicants: The Governors of the University of A6IN5/06 (2006.01) Alberta, Edmonton (CA); The (52) U.S. Cl. University of Lethbridge, Lethbridge CPC ......... A61N5/0616 (2013.01); A61N 2005/066 (CA) (2013.01) (72) Inventors: Lyubov Titova, Edmonton (CA); Frank Hegmann, Edmonton (CA); Olga (57) ABSTRACT Kovalchuk, Lethbridge, (CA) (21) Appl. No.: 14/615,153 The disclosure provides methods for the treatment of skin disorders through the use of minimally invasive terahertz (22) Filed: Feb. 5, 2015 radiation. The method includes exposing skin cells to tera hertz radiation in amount Sufficient to modulate gene expres Related U.S. Application Data sion in the skin cells. The modulation of gene expression then (60) Provisional application No. 61/936,627, filed on Feb. results in a reduction of the disease state or aspects thereof in 6, 2014. the exposed skin cells. S.. R S S. & S. S. S. S. & S. S. S.s S ŠS. S.S. ^x S.S. & S.N SS. S.S S S. S S S S R S. Ski SS 8 in a single wei inset Patent Application Publication Aug. 6, 2015 Sheet 1 of 60 US 2015/0217131 A1 º?%-?.- & & cy Figure 1A Figure 1B Figure 1C Patent Application Publication Aug. 6, 2015 Sheet 2 of 60 US 2015/0217131 A1 Staturn E. S as Figure 1D S S.
[Show full text]